E-LIB Suche - Ergebnisse für: Nardinelli, Clark

1

Prospective Evaluation of Health Communication Effects on M..:

Summers, Rosemarie L. ; Wood, Dallas W. ; Lew, Nellie...
Journal of Benefit-Cost Analysis. 13 (2022) 1 - p. 34-56 , 2022

Link: https://doi.org/10.1017/..

2

Willingness to pay to standardize patient medication inform..:

Dealy, Bern Caudill ; Kearsley, Aaron ; Wolff, Carolyn...
Applied Economics. 53 (2020) 9 - p. 1112-1126 , 2020

Link: https://doi.org/10.1080/..

3

A Retrospective and Commentary on FDA's Bar Code Rule:

Kearsley, Aaron ; Lew, Nellie ; Nardinelli, Clark
Journal of Benefit-Cost Analysis. 9 (2018) 3 - p. 496-518 , 2018

Link: https://doi.org/10.1017/..

4

The signaling effects of incremental information: Evidence ..:

Miller, Kathleen L. ; Nardinelli, Clark ; Pink, George.
The Quarterly Review of Economics and Finance. 67 (2018) - p. 219-226 , 2018

Link: https://doi.org/10.1016/..

5

Some Pitfalls of Practical Benefit-Cost Analysis:

Nardinelli, Clark
Journal of Benefit-Cost Analysis. 9 (2018) 3 - p. 519-530 , 2018

Link: https://doi.org/10.1017/..

6

Evaluation of Pre-marketing Factors to Predict Post-marketi..:

Schick, Andreas ; Miller, Kathleen L. ; Lanthier, Michael..
Drug Safety. 40 (2017) 6 - p. 497-503 , 2017

Link: https://doi.org/10.1007/..

7

The Signaling Effects of the US Food and Drug Administratio..:

Miller, Kathleen L. ; Nardinelli, Clark ; Pink, George.
Managerial and Decision Economics. 38 (2017) 4 - p. 581-594 , 2017

Link: https://www.jstor.org/st..

8

The Signaling Effects of the US Food and Drug Administratio..:

Miller, Kathleen L. ; Nardinelli, Clark ; Pink, George.
Managerial and Decision Economics. 38 (2016) 4 - p. 581-594 , 2016

Link: https://doi.org/10.1002/..

9

The Per Case and Total Annual Costs of Foodborne Illness in..:

Minor, Travis ; Lasher, Angela ; Klontz, Karl...
Risk Analysis. 35 (2015) 6 - p. 1125-1139 , 2015

Link: https://doi.org/10.1111/..

10

Estimating the Benefits of Public Health Policies that Redu..:

Ashley, Elizabeth M. ; Nardinelli, Clark ; Lavaty, Rosemarie A.
Health Economics. 24 (2014) 5 - p. 617-624 , 2014

Link: https://doi.org/10.1002/..

11

Atomoxetine Use During a Period of FDA Actions:

Du, Dongyi Tony ; Zhou, Esther H. ; Goldsmith, John..
Medical Care. 50 (2012) 11 - p. 987-992 , 2012

Link: https://www.jstor.org/st..

12

Integrating Risk Assessment and Cost Benefit Analysis: An E..:

, In: Ensuring Global Food Safety,

McLaughlin, Cristina ; Vardon, Peter ; Nardinelli, Clark - p. 439-440 , 2010

Link: https://doi.org/10.1016/..

13

An exploratory study of FDA new drug review times, prescrip..:

Vernon, John A. ; Golec, Joseph H. ; Lutter, Randall.
The Quarterly Review of Economics and Finance. 49 (2009) 4 - p. 1260-1274 , 2009

Link: https://doi.org/10.1016/..

14

Economic issues with follow-on protein products:

Lanthier, Michael ; Behrman, Rachel ; Nardinelli, Clark
Nature Reviews Drug Discovery. 7 (2008) 9 - p. 733-737 , 2008

Link: https://doi.org/10.1038/..

15

Black Box Warnings and Drug Safety: Examining the Determina..

NBER working paper series, no. w12803

Begosh, Allan ; Goldsmith, John ; Hass, Ed... , 2006

Link: https://www.nber.org/pap..